Long-term engraftment and phenotype correction has been difficult to achieve in humans after in utero stem cell transplantation mainly because of allogeneic rejection. Autologous cells could be obtained during gestation from the amniotic fluid with minimal risk for the fetus and the mother. Using a sheep model, we explored the possibility of using amniotic fluid mesenchymal stem cells (AFMSCs) for autologous in utero stem cell/gene therapy. We collected amniotic fluid (AF) under ultrasound-guided amniocentesis in early gestation pregnant sheep ( n = 9, 58 days of gestation, term = 145 days). AFMSCs were isolated and expanded in all sampled fetal sheep. Those cells were transduced using an HIV vector encoding enhanced green fluorescent protein (GFP) with 63.2

作者：S W Steven, Shaw；Sveva, Bollini；Khalil Abi, Nader；Annalisa, Gastaldello；Vedanta, Mehta；Elisa, Filppi；Mara, Cananzi；H Bobby, Gaspar；Waseem, Qasim；Paolo, De Coppi；Anna L, David

来源：Cell transplantation 2016 年 25卷 3期